Inventor · disambiguated record
Barbra Johnson Sasu
Also filed as: SASU BARBRA · SASU BARBRA JOHNSON
28 granted patents·19 pending applications·69 citations·filing 2007–2024
94Inventor score
Top patents by PatentIndex Score
47 records- 0193US11673953B2DLL3 targeting chimeric antigen receptors and binding agentsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·9 cites·31 claims
- 0292US11377500B2Antibodies specific for CD70 and their usesPFIZER·Filed 2019·Granted Jul 5, 2022·8 cites·36 claims
- 0392US10294304B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2016·Granted May 21, 2019·16 cites·22 claims
- 0485US11396551B2Chimeric antigen receptors targeting CD70PFIZER·Filed 2019·Granted Jul 26, 2022·2 cites·47 claims
- 0585US11014989B2Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapyCELLECTIS·Filed 2016·Granted May 25, 2021·2 cites·24 claims
- 0684US11072644B2Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2015·Granted Jul 27, 2021·2 cites·21 claims
- 0784US8629250B2Hepcidin, hepcidin antagonists and methods of useSASU BARBRA·Filed 2008·Granted Jan 14, 2014·14 cites·15 claims
- 0882US11312782B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2019·Granted Apr 26, 2022·1 cites·46 claims
- 0980US10221242B2Antibodies specific for epidermal growth factor receptor variant III and their usesPFIZER·Filed 2017·Granted Mar 5, 2019·4 cites·25 claims
- 1079US12036243B2BCMA CAR-T cells with enhanced activitiesALLOGENE THERAPEUTICS INC·Filed 2021·Granted Jul 16, 2024·1 cites·32 claims
- 1179US10259876B2Chimeric antigen receptors targeting epidermal growth factor receptor variant IIIPFIZER·Filed 2017·Granted Apr 16, 2019·3 cites·21 claims
- 1278US2025145725A1Chimeric antigen receptors targeting cd70PFIZER·Filed 2024·Application pending·0 cites
- 1378US2024360196A1Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1478US2025011446A1Antibodies specific for cd70 and their usesPFIZER·Filed 2024·Application pending·0 cites
- 1577US9175078B2Ferroportin antibodies and methods of useARVEDSON TARA·Filed 2009·Granted Nov 3, 2015·6 cites·53 claims
- 1676US12447178B2Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2023·Granted Oct 21, 2025·0 cites·21 claims
- 1775US12152081B2Chimeric antigen receptors targeting CD70PFIZER·Filed 2022·Granted Nov 26, 2024·0 cites·42 claims
- 1875US11987634B2Antibodies specific for CD70 and their usesPFIZER·Filed 2022·Granted May 21, 2024·0 cites·33 claims
- 1975US11279764B2Antibodies specific for epidermal growth factor receptor variant III and their usesPFIZER·Filed 2018·Granted Mar 22, 2022·1 cites·35 claims
- 2075US2025230410A1Chimeric antigen receptors with enhanced signaling and activities and uses thereofALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2173US11912776B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 2272US2025171731A1Methods of manufacturing allogeneic car t cellsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2372US2025051421A1Constitutively active chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2470US2024016846A1Chimeric cytokine receptors bearing a pd-1 ectodomainALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2570US2022227874A1Chimeric antigen receptors targeting epidermal growth factor receptor variant iiiPFIZER·Filed 2022·Application pending·0 cites
- 2669US2025207199A1Methods for detecting genomic abnormalities in cellsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2768US12215347B2Chimeric antigen receptors with enhanced signaling and activities and uses thereofALLOGENE THERAPEUTICS INC·Filed 2021·Granted Feb 4, 2025·0 cites·12 claims
- 2867US2022033462A1Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2964US2024003056A1Anti-talen antibodies and uses thereofALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3063US11267892B2Chimeric antigen receptors targeting epidermal growth factor receptor variant IIIPFIZER·Filed 2019·Granted Mar 8, 2022·0 cites·48 claims
- 3162US2024216430A1Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereofALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3261US12404315B2Protease-activating CD45-gate CARALLOGENE THERAPEUTICS INC·Filed 2021·Granted Sep 2, 2025·0 cites·35 claims
- 3361US12043655B2Constitutively active chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jul 23, 2024·0 cites·39 claims
- 3461US11896617B2Polynucleotides encoding rituximab-resistant chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Feb 13, 2024·0 cites·23 claims
- 3561US11786553B2Chimeric cytokine receptors bearing a PD-1 ectodomainALLOGENE THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·0 cites·33 claims
- 3661US2024042030A1Engineered cells with reduced gene expression to mitigate immune cell recognitionALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3761US2023407252A1Methods for donor cell analysisALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3860US12163153B2Methods of manufacturing allogeneic CAR T cellsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Dec 10, 2024·0 cites·18 claims
- 3960US11781248B2Anti-TALEN antibodies and uses thereofALLOGENE THERAPEUTICS INC·Filed 2020·Granted Oct 10, 2023·0 cites·23 claims
- 4060US2022409665A1Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistenceALLOGENE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4159US2023346934A1Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signalsALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4254US2014286953A1Hepcidin, hepcidin antagonists and methods of useAMGEN INC·Filed 2013·Application pending·0 cites
- 4354US2009173876A1Method of detecting and/or measuring hepcidin in a sampleAMGEN INC·Filed 2007·Application pending·0 cites
- 4451US11732041B2Antibodies against 4G7-derived chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Aug 22, 2023·0 cites·29 claims
- 4551US2011312888A1Method of detecting and/or measuring hepcidin in a sampleLI HONGYAN·Filed 2011·Application pending·0 cites
- 4646US9688759B2Ferroportin antibodies and methods of useAMGEN INC·Filed 2015·Granted Jun 27, 2017·0 cites·12 claims
- 4739US12296012B2Chimeric antigen receptors targeting FLT3PFIZER·Filed 2018·Granted May 13, 2025·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Barbra Johnson Sasu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →